PD1/PD-L1 inhibition may improve the antitumoral activity of R-MΦs and conversely, CSF1R inhibition may improve the effect of anti-PD1/PD-L1 monoclonal antibody in relapsed/refractory AML. The gene discussed is CD274; the disease is acute myeloid leukemia.